A reassessment of risks and benefits of dopamine agonists in Parkinson's disease

被引:146
作者
Antonini, Angelo [2 ]
Tolosa, Eduardo [3 ,4 ]
Mizuno, Yoshikuni [5 ]
Yamamoto, Mitsutoshi [6 ]
Poewe, Werner H. [1 ]
机构
[1] Med Univ Innsbruck, Dept Neurol, Anichstr 35, A-6020 Innsbruck, Austria
[2] Ist Clin Perfezionamento, Parkinson Inst, Milan, Italy
[3] Univ Barcelona, Hosp Clin, Neurol Serv, Barcelona, Spain
[4] CIBERNED, Barcelona, Spain
[5] Juntendo Univ, Sch Med, Dept Neurol, Tokyo 113, Japan
[6] Kagawa Prefectural Cent Hosp, Dept Neurol, Kagawa, Japan
关键词
EXCESSIVE DAYTIME SLEEPINESS; IMPULSE CONTROL DISORDERS; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; RETROPERITONEAL FIBROSIS; TRANSDERMAL ROTIGOTINE; HEART-DISEASE; PLEUROPULMONARY FIBROSIS; PERGOLIDE MONOTHERAPY; MOTOR COMPLICATIONS;
D O I
10.1016/S1474-4422(09)70225-X
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Neurologists have several choices of drugs that have been shown to be effective for the treatment of the symptoms of Parkinson's disease. Among the first options are the dopamine agonists, which are commonly used both as an early monotherapy and as an adjunct therapy to levodopa. However, before starting any treatment, the overall benefit-to-risk ratio to individual patients must be considered. For the dopamine agonists, the available evidence on their symptomatic efficacy, effect on long-term levodopa-related motor complications, putative effect on progression of disease, and adverse event profile must be taken into account. Recently, the ocurrence of adverse events such as leg oedema, daytime somnolence, impulse control disorders, and fibrosis have increasingly been recognised. The risks of these potentially serious adverse events must therefore be taken into account and treatment decisions should be based on considerations of risks versus benefits for individual patients.
引用
收藏
页码:929 / 937
页数:9
相关论文
共 110 条
[61]   Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease [J].
Paus, S ;
Brecht, HM ;
Köster, J ;
Seeger, G ;
Klockgether, T ;
Wüllner, U .
MOVEMENT DISORDERS, 2003, 18 (06) :659-667
[62]  
*PDTRIALS, PRIM OBJ STRIDE PD S
[63]  
POEWE W, 1993, ADV NEUROL, V60, P656
[64]   Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial [J].
Poewe, Werner H. ;
Rascol, Olivier ;
Quinn, Niall ;
Tolosa, Eduardo ;
Oertel, Wolfgang H. ;
Martignoni, Emilia ;
Rupp, Markus ;
Boroojerdi, Babak .
LANCET NEUROLOGY, 2007, 6 (06) :513-520
[65]   VaIvular heart disease in patients taking pergolide [J].
Pritchett, AM ;
Morrison, JF ;
Edwards, WD ;
Schaff, HV ;
Connolly, HM ;
Espinosa, RE .
MAYO CLINIC PROCEEDINGS, 2002, 77 (12) :1280-1286
[66]   Treatment interventions for Parkinson's disease: an evidence based assessment [J].
Rascol, O ;
Goetz, C ;
Koller, W ;
Poewe, W ;
Sampaio, C .
LANCET, 2002, 359 (9317) :1589-1598
[67]   A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa [J].
Rascol, O ;
Brooks, DJ ;
Korczyn, AD ;
De Deyn, PP ;
Clarke, CE ;
Lang, AE .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (20) :1484-1491
[68]   Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study [J].
Rascol, Olivier ;
Dubois, Bruno ;
Caldas, Alexandre Castro ;
Senn, Stephen ;
Del Signore, Susanna ;
Lees, Andrew .
MOVEMENT DISORDERS, 2006, 21 (12) :2110-2115
[69]   The role of radiotracer imaging in Parkinson disease [J].
Ravina, B ;
Eidelberg, D ;
Ahlskog, JE ;
Albin, RL ;
Brooks, DJ ;
Carbon, M ;
Dhawan, V ;
Feigin, A ;
Fahn, S ;
Guttman, M ;
Gwinn-Hardy, K ;
McFarland, H ;
Innis, R ;
Katz, RG ;
Kieburtz, K ;
Kish, SJ ;
Lange, N ;
Langston, JW ;
Marek, K ;
Morin, L ;
Moy, C ;
Murphy, D ;
Oertel, WH ;
Oliver, G ;
Palesch, Y ;
Powers, W ;
Seibyl, J ;
Sethi, KD ;
Shults, CW ;
Sheehy, P ;
Stoessl, AJ ;
Holloway, R .
NEUROLOGY, 2005, 64 (02) :208-215
[70]   Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications - Results of a double-blind levodopa controlled trial [J].
Rinne, UK ;
Bracco, F ;
Chouza, C ;
Dupont, E ;
Gershanik, O ;
Masso, JFM ;
Montastruc, JL ;
Marsden, CD .
DRUGS, 1998, 55 (Suppl 1) :23-30